News Center
-91.jpg)
All
2025
2024
2023
2022
2021
2020
-
LaNova Medicines' LM-302 receives NMPA IND Approval2021-10-15
Learn More
-
LaNova Medicines Holds Townhall Meeting to Celebrate 2nd Company Anniversary2021-10-02Learn More
-
LaNova Medicines Moved to Its New Office at 999 Cailun Road in Zhangjiang Science Park
On August 2nd, 2021, LaNova Medicines moved to its brand-new office at 999 Cailun Road on Jinke Road in Zhangjiang Science Park, with expanded laboratory and office space. More than 40 employees gathered together in the hall of the new office, and the fou
2021-08-03Learn More
-
LM-102 Obtained China NMPA Clinical Trial Approval
LM-102 received China NMPA approval for its China phase I/II clinical study.
2021-06-23Learn More
-
LM-102 Obtained FDA Clinical Trial Approval and Completed First Patient Dosing
LM-102 obtained FDA clinical trial approval early this year as a phase I clinical study designed to evaluate the safety and initial efficacy of LM-102.
2021-06-22Learn More
-
LM-302 Obtained FDA Clinical Trial Approval
Claudin 18.2 ADC LM-302 obtained US FDA clinical study approval. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-302.
2021-06-21Learn More